GlassScriptPhysician profile
John Daniel Legge
NPI 1962898783
$10,091.20
in general payments reported to CMS, 2019-2025
19 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,299 · 2020: $1,395 · 2021: $2,075 · 2022: $439 · 2023: $556 · 2024: $183 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $874 · Education: $9.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $873.99 |
| Education | $9.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $4,806.64 | 2019 | |
| Abbott Laboratories | $1,534.86 | 2019-2023 | Infinity |
| Avion Pharmaceuticals | $1,460.00 | 2021 | |
| Boston Scientific Corporation | $1,295.31 | 2019-2025 | General - Dbs |
| Abbvie INC. | $362.09 | 2021-2024 | |
| Acadia Pharmaceuticals INC | $150.91 | 2019-2020 | |
| Mdd US Operations, LLC | $108.30 | 2020-2022 | |
| Merz North America, INC. | $57.49 | 2020 | |
| Acorda Therapeutics, INC | $46.25 | 2019 | |
| Amgen INC. | $42.99 | 2020-2021 | |
| Adamas Pharmaceuticals, INC. | $41.93 | 2020 | |
| Neurocrine Biosciences, INC. | $37.79 | 2019 | |
| Allergan, INC. | $36.99 | 2022 | |
| Lundbeck LLC | $36.46 | 2019 | |
| Kyowa Kirin, INC. | $19.90 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $16.93 | 2019 | |
| Amneal Pharmaceuticals LLC | $16.19 | 2019 | |
| Emd Serono, INC. | $12.13 | 2020 | |
| Travere Therapeutics, INC. | $8.04 | 2021-2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Legge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.